Plasma microRNA signatures to predict EGFR-TKI resistance in EGFR-mutant advanced NSCLC patients.

被引：0
|
作者：
Wang, Shuhang
Wang, Jie
Bai, Hua
An, Tongtong
Zhao, Jun
Wang, Zhijie
Duan, Jianchun
Zhuo, Minglei
Wang, Yuyan
Wu, Meina
机构：
[1] Beijing Canc Hosp, Minist Educ, Key Lab Carcinogenesis & Translat Res, Beijing, Peoples R China
[2] Peking Univ, Canc Hosp, Sch Oncol, Beijing Canc Hosp, Beijing 100871, Peoples R China
[3] Peking Univ, Sch Oncol, Beijing Canc Hosp & Inst, Beijing 100871, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e19136
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Brain metastasis, EGFR mutation subtype and generation of EGFR-TKI jointly influence the treatment outcome of patient with EGFR-mutant NSCLC
    Ju J.-S.
    Huang A.C.-C.
    Tung P.-H.
    Huang C.-H.
    Chiu T.-H.
    Wang C.-C.
    Ko H.-W.
    Chung F.-T.
    Hsu P.-C.
    Fang Y.-F.
    Guo Y.-K.
    Kuo C.-H.S.
    Yang C.-T.
    [J]. Scientific Reports, 13 (1)
  • [22] Factors affecting PS deterioration at the time of relapse after the first-line EGFR-TKI therapy in EGFR-mutant advanced NSCLC
    Tamura, Tomoki
    Hotta, Katsuyuki
    Gotoda, Hiroko
    Kato, Yuka
    Ichihara, Eiki
    Kubo, Toshio
    Tanimoto, Mltsune
    Kiura, Katsuyuki
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [23] Risk Stratification Using a Novel Nomogram for 2190 EGFR-Mutant NSCLC Patients Receiving the First or Second Generation EGFR-TKI
    Chang, John Wen-Cheng
    Huang, Chen-Yang
    Fang, Yueh-Fu
    Chang, Ching-Fu
    Yang, Cheng-Ta
    Kuo, Chih-Hsi Scott
    Hsu, Ping-Chih
    Wu, Chiao-En
    [J]. CANCERS, 2022, 14 (04)
  • [24] The Multi-Omics Analysis of Key Genes Regulating EGFR-TKI Resistance, Immune Infiltration, SCLC Transformation in EGFR-Mutant NSCLC
    Wang, Zhi
    Zhang, Lingling
    Xu, Wenwen
    Li, Jie
    Liu, Yi
    Zeng, Xiaozhu
    Zhong, Maoxi
    Zhu, Yuxi
    [J]. JOURNAL OF INFLAMMATION RESEARCH, 2022, 15 : 649 - 667
  • [25] The Difference in Clinical Outcomes Between Osimertinib and EGFR-TKI plus Anti-angiogenic Agent in EGFR-mutant NSCLC Patients
    Huang, Y. H.
    Hsu, K. -H.
    Tseng, J. -S.
    Chen, K. -C.
    Chang, G. -C.
    Yang, T. -Y.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S477 - S478
  • [26] Concurrent Brain Radiotherapy and EGFR-TKI Have Better Survival Benefits in Patients with Brain Metastases from EGFR-Mutant NSCLC
    Zhu, Y.
    Chen, Y.
    Han, S.
    Ying, X.
    Sun, X.
    Xu, Y.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S502 - S502
  • [27] EGFR-mutant NSCLC may remodel TME from non-inflamed to inflamed through acquiring resistance to EGFR-TKI treatment
    Chen, Qianqian
    Xia, Liliang
    Wang, Jingze
    Zhu, Shuxin
    Wang, Jing
    Li, Xing
    Yu, Yongfeng
    Li, Ziming
    Wang, Ying
    Zhu, Guanshan
    Lu, Shun
    [J]. LUNG CANCER, 2024, 192
  • [28] EGFR-TKI plus /- Antiangiogenics for EGFR-mutated Advanced NSCLC
    da Silva, L. L.
    Matsas, S.
    Aguiar, P., Jr.
    Taveira, G. M. T.
    Barcelos, I. F.
    Lopes, G. L., Jr.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S416 - S417
  • [29] Concurrent use of anlotinib overcomes acquired resistance to EGFR-TKI in patients with advanced EGFR-mutant non-small cell lung cancer
    Zhang, Chen
    Cao, Honggang
    Cui, Yanan
    Jin, Shidai
    Gao, Wen
    Huang, Chenjun
    Guo, Renhua
    [J]. THORACIC CANCER, 2021, 12 (19) : 2574 - 2584
  • [30] Retreatment with EGFR-TKI for 541 NSCLC Patients with EGFR Mutation
    Takahashi, K.
    Ito, K.
    Murotani, K.
    Asada, K.
    Okuno, M.
    Kimura, T.
    Kubo, A.
    Suda, T.
    Taniguchi, H.
    Hataji, O.
    Shindo, J.
    Kunii, E.
    Yoshida, T.
    Imaizumi, K.
    Hida, T.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S833 - S833
12345